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Abstract
Background: Multiple sclerosis (MS) is one of the most frequently observed neurological conditions in Switzerland,
but data sources for country-wide epidemiological trend monitoring are lacking. Moreover, while clinical and laboratory
MS research are generally well established, there is a gap in patient-centered MS research to inform care management,
or treatment decisions and policy making not only in Switzerland but worldwide.
Methods: In light of these research gaps, the Swiss Multiple Sclerosis Society initiated and funded the Swiss Multiple
Sclerosis Registry (SMSR) an open-ended, longitudinal and prospective, nationwide, patient-centered study.
The SMSR recruits adult persons with a suspected or confirmed MS diagnosis who reside or receive care in Switzerland.
The SMSR has established a governance structure with clear rules and guidelines. It follows a citizen-science approach
with direct involvement of persons with MS (PwMS), who contribute actively to registry development, operations, and
research. Main scientific goals entail the study of MS epidemiology in Switzerland, health care access and provision, as
well as life circumstances and wellbeing of persons with MS.
The innovative study design (“layer model”) offers several participation options with different time commitments. Data
collection is by means of regular surveys and medical record abstraction. Survey participation is offered in different modes
(web, paper & pencil) and in the three main national languages (German, French, Italian). Participants also receive regular
data feedbacks for personal use and self-monitoring, contextualized in the whole population of study participants. Data
feedbacks are also used to solicit data corrections of key variables from participants.
Discussion: The SMSR combines the advantages of traditional and novel research methods in medical research and has
recruited over 1600 PwMS in its first year. The future-oriented design and technology will enable a response not only to
future technological innovations and research trends, but also to challenges in health care provision for MS.
Trial registration: ClinicalTrials.gov NCT02980640; December 6, 2016; retrospectively registered.
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Background
Multiple sclerosis (MS) is the most common cause of
non-traumatic disability among young adults in industri-
alized countries [1]. With an estimated 110 MS cases
per 100,000 inhabitants, [2] the MS prevalence in
Switzerland surpasses the median estimate for Europe
- the region with the highest MS prevalence worldwide
(80 per 100,000 inhabitants) [3]. However, the Swiss
estimate has not been updated in nearly 30 years,
mostly because no easily accessible routine data are
available, for example from clinical care or health in-
surances. Unlike countries with national health care
systems, the highly fragmented Swiss health care land-
scape suffers from a lack of standardization in data
collection, an inexistent legal basis for mandatory
reporting of severe chronic illnesses, as well as limited
information technology (IT) system interoperability
between different care and health insurance providers.
In light of these constraints, the establishment of a
medical registry with active data collection from vari-
ous sources is one of very few viable options for
establishing a long-term monitoring of epidemiological
trends, but also for promoting personalized medicine
approaches in MS [4].
As illustrated by a systematic survey of European MS
registries, the role of registries in MS research is not
limited to monitoring purposes [5]. The international
MS registry landscape is very diverse, and many of these
studies have made important contributions to MS epi-
demiology, treatment, diagnosis, and care research.
However, several other disease aspects are less well cov-
ered by some existing registries, such as cost of illness,
quality management of healthcare, patient preferences,
and patient reported outcomes [5]. These research limi-
tations can weigh heavy in chronic illnesses such as MS,
often characterized by a complex management, an un-
clear evidence base for treatment guidelines, and on
the important role of patient preferences in treatment
decisions.
These two issues, a lack of epidemiological data for
Switzerland and the promotion of the patient-perspective
in MS research, triggered the Swiss MS Society to estab-
lish a novel MS registry. The Swiss MS Registry (SMSR)
not only contributes basic data on the epidemiology of
MS in Switzerland, through its patient-centered design it
can also fill an important niche in national and inter-
national research together with other studies [5, 6]. This
manuscript describes the main philosophy behind the
SMSR and elaborates on the study design, as well as the
methods and contents of the data collection. Moreover, a
companion paper illustrates how the SMSR merges trad-
itional with novel, internet-driven research approaches to
leverage the advantages of both while mitigating legal, eth-
ical, and data security risks [7].
Methods/Design
Study objectives
The SMSR was established with three primary goals.
First, the SMSR shall provide the basis for more accurate
prevalence estimates and long-term monitoring of epi-
demiological trends of MS in Switzerland.
Second, the SMSR will establish a study base for
patient-centered MS research in Switzerland, thereby
focusing on assessments of the disease burden for per-
sons with MS (PwMS) and their relatives and proxies.
Along the same lines, the SMSR aims to contribute re-
search to previously understudied topics concerning
patients’ life circumstances and experiences (e.g. MS
and work), as well as on clinical and health care related
aspects (e.g. access to specialized MS care).
Third, by creating a versatile database and a flexible
study infrastructure, the SMSR offers a platform for
nested investigations. From the outset, the SMSR aimed
to be an interdisciplinary, open, collaborative project, de-
signed to leverage other existing research efforts. In par-
ticular, by systematic analysis of the Swiss and the
international MS research landscape [5], knowledge gaps
were identified and subsequently taken into account dur-
ing the study planning phase. Examples of such topics
include health-related quality of life, alternative medi-
cines, physiotherapy, or work and insurance, which have
now become part of the SMSR core data collection. Fur-
thermore, the SMSR data structures were designed for
compatibility with ongoing national and international
collaborations (EUReMS) [8]. Specifically, the SMSR has
established a strategic partnership with the clinically-ori-
ented Swiss MS Cohort (SMSC) study [9] and strives to
complement the SMSC data collection by adding further
data from the patients’ perspectives on diagnosis, treat-
ment, and general well-being. In both studies, informed
consent documents include opt-in agreements to allow
future data exchanges between the SMSR and the SMSC
for data validation and research projects.
Study design
The SMSR is an open-ended, longitudinal and prospective,
nationwide, patient-centered study (http://www.Clinical-
Trials.gov identifier: NCT02980640). It follows a
citizen-science approach with direct involvement of PwMS,
who contribute to the SMSR development and research via
representation in the Scientific Assembly.
Unlike other MS registries, the data are primarily col-
lected directly from participants via structured question-
naires, that is, without intermediary health professionals.
Consequently, surveys must be understandable by
lay-persons and be provided in the three main Swiss
official languages (German, French, Italian). Participa-
tion is offered via an online web system and as paper
& pencil versions.
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Design and the research strategy of the SMSR are
based on three major tenets, which were flexibility re-
garding study contribution by PwMS (from one-time to
longitudinal participation), provision of data feedbacks
to participants and regular information on how data are
being used, as well as the involvement of PwMS in study
design and execution.
The SMSR includes four participation options for
PwMS: (1) they can simply fill in a one-time survey, (2)
additionally they can complete regular, semi-annual sur-
veys on varying topics, (3) when signing the informed
consent, they can decide to grant access to their medical
records for abstraction by the SMSR, and (4) partici-
pants can allow the SMSR to exchange their data with
the SMSC. Combinations of these options are possible.
The decision for participation in either study module
needs to be taken at time to informed consent signature
(layer 1) on an opt-in basis but can be revised later, for
example if a person wishes to withdraw her/his consent
for medical record release.
These different participation forms are also reflected
(and accommodated) in the SMSR study design, which
entails different layers (Fig. 1) through which partici-
pants can gradually navigate. This layer concept was in-
spired by the amyotrophic lateral sclerosis registry in the
USA [10]. The first, outermost layer 1 includes the de-
position of contact information and informed consent
signature. During these steps, prospective participants
can also decide on which study modules they would like
to contribute to.
The SMSR registration process is considered complete
upon submission of a first, one-off questionnaire, which
also demarks the second registry layer. The purpose of
layer 2 is to collect basic demographic and medical data
from as many PwMS as possible for epidemiological in-
vestigations (e.g. on MS prevalence in Switzerland).
In layer 3, the SMSR further offers regular participa-
tion by means of semi-annual surveys. The main object-
ive of this third layer is a longitudinal data collection on
disease burden, MS progression, physical and mental
well-being, and changing life circumstances (Table 1).
Layer 3 is open to all participants who have completed
layer 2 and are willing to submit a confirmation of their
diagnosis, signed by their treating physician.
The self-reported data from layers 1 to 3 are com-
plemented by clinical data in layer 4, which stems
from two sources. Participants may either elect to re-
lease their patient charts for medical record abstrac-
tion or they can allow data exchanges between the
SMSR and the SMSC in case of dual participation in
both studies. These clinical layer 4 data are of critical
importance for validation of self-reported medical
events such as symptoms, relapses, comorbidities, and
treatments. The goal is to document up to 1000 par-
ticipants, and the patient selection for layer 4 medical
record abstraction is made by the SMSR study center
based on age, gender, disease stage, and treatment
setting in order to ensure representativeness.
Layers 3 and 4 also allow data collections for specific pro-
jects, which can either be included into regular follow-up
surveys and data abstractions or be conducted as separate
nested measurements outside the regular follow-up sched-
ule (but possibly requiring its own ethical approval / in-
formed consent). Combined, the layer design offers a very
flexible structure, which not only accommodates specific
research needs, but also offers participants a choice of dif-
ferent commitment levels.
Study population
The SMSR is open to all adults aged 18 years and older
who were diagnosed with MS or a clinically isolated
syndrome (CIS) and who live or are regularly receiving
medical care in Switzerland. For contribution to layers
3 and 4, the MS/CIS diagnosis needs to be confirmed
by a physician.
Study recruitment
The SMSR was initiated by and developed in close
collaboration with the MS community in Switzerland,
represented by the Swiss MS Society. The SMSR is
Fig. 1 Study design of the Swiss Multiple Sclerosis Registry (SMSR)
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Table 1 Overview of assessments in the Swiss Multiple Sclerosis Registry
Topics Layer 2
(one-off Survey)
Layer 3 Baseline
(one-off Survey)
Layer 3 Follow-up 1
(every 6 months)
Layer 3 Follow-up 2
(every 12 months)
Layer 4 (Medical chart
review every 12 months)
Sociodemographic variables
Personal information X X X
Family and living situation X X X
Education, profession X X
Working situation X X
Occupational changes due to MS X X
Societal context (e.g. disability insurance) X X
Disease course
First symptoms X X
Symptoms ever, current X X X X X
Symptoms changes (prior and after
diagnosis)
X
Disease stage, type of MS X X X X X
EDSS-score X X X X
Mobility X X
Relapses X X X X
Age of disease progression X
Diagnostic process
Age at first symptoms X
Time of first medical doctor visit X
Personal experience of diagnostic process X
Treatment
Disease modifying treatment ever/current X X X X X
Non-drug therapies X X X X X
Side effects / adverse events X X X X X
Therapy stop / interruption X X X X
Interventions against side effects X X X X
Alternative medicine X X X X
Additional medicine / supplements X X X X
Cannabis treatment X X X
Comorbidities
Comorbidities X X X X
Medication for comorbidities X X X X
Risk factors and family history
Weight X X
Smoking behavior (and exposure) X X
Alcohol consumption X X
Nutrition X X
Previous medical history X
Childhood illnesses X
Vaccination X X
MS family history X X
Sun exposure X
Hormonal factors (only women) X
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executed by the University of Zurich and promoted
as a project of the Swiss MS Society. The Society’s
extensive network and various media outlets (website,
member magazine, social media activities, newsletters)
allowed a quick and nationwide dissemination of in-
formation about the SMSR to potentially interested
participants, as well as physicians.
Registry enrolment occurs by means of self-recruitment
and peer referral. Clinics and private practices are involved
in recruitment insofar as they provide postcards and leaf-
lets about the SMSR and raise awareness of the Registry’s
existence among their patients. For SMSR enrolment, in-
terested persons can either send in a postcard to the
SMSR data center, upon which they will receive additional
instructions for joining the SMSR. Alternatively, they can
login directly to a website (www.ms-register.ch), create an
account, and - after signing the informed consent- access
the surveys.
Ethical aspects
The study has been approved for nationwide conduct
as a multi-centric study by the Ethics Committee
Zurich (Study number PB-2016-00894). Informed con-
sent is obtained from all participants, either electron-
ically upon first access to the SMSR platform or as
part of the registration process for participants who
prefer paper & pencil versions. In line with the SMSR’s
strategy to offer various commitment levels, the in-
formed consent offers three opt-in choices regarding
study module participation.
The first module involves the diagnosis confirmation,
which is prerequisite for participation in regular follow-up
surveys (layer 3) and medical record abstraction (layer 4).
That is, refusal of providing permission of the diagnosis
confirmation by the treating physician implies that only
participation in layer 2 is possible.
The second module is the medical record abstraction.
Giving approval to this study option means providing
the SMSR data center personnel access to medical re-
cords. Prior to first record access, participants are noti-
fied and given 3 weeks to notify the SMSR data center in
case they wish to reconsider their decision.
Third, SMSR participants can agree to share their data
with the SMSC study and vice versa. This study module
Table 1 Overview of assessments in the Swiss Multiple Sclerosis Registry (Continued)
Topics Layer 2
(one-off Survey)
Layer 3 Baseline
(one-off Survey)
Layer 3 Follow-up 1
(every 6 months)
Layer 3 Follow-up 2
(every 12 months)
Layer 4 (Medical chart
review every 12 months)
Nutrition and Lifestyle
Nutrition change since diagnosis X X
Lifestyle change since diagnosis X X
Physical Activity X X X
Care and medical aids
Institutions visits X X X
Care types X X
Contact with healthcare professionals X X X
Specialists consultation X X X
Confidence in specialists X X
Medical aids X X
Domestic assistance X X
Housework X X
Disclosure of MS X X
Quality of Life
Health related quality of life (EQ-5D-
5 L;WHO 5-item well-being index)
X X X X
Mental health
Psychological well-being X X X X
Depression X X X
Burden of disease
Individual burden (e.g. symptoms,...) X X X X
Societal burden X X X
Economic burden X
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only applies to persons enrolled in both studies. Overall,
agreement to these three study modules is in excess of
90%. Withdrawal from any of these study modules or
from SMSR participation is possible at any time and
without provision of explanations, but very few persons
have chosen to do so (< 20 participants).
Data acquisition
Data are collected directly from participants via structured
questionnaires. The entry questionnaire, which constitutes
layer 2, takes approximately 20 min to complete and col-
lects data on a person’s MS history, symptoms, treat-
ments, diagnosis, risk factors, as well as changes in
lifestyle behavior due to MS (Table 1). Approx. 75% of all
layer 2 participants also contribute to the regular surveys
in layer 3. These semi-annual questionnaires require
45 min and collect data on recent medical events, drug-
and non-drug treatments, living and familial situation,
work and evolving special topics (e.g. on patients’ experi-
ences of the diagnostic process). Participants are either in-
formed via email when a new questionnaire is ready or, in
case of participation on paper, the survey is mailed dir-
ectly, along with a pre-stamped return envelope. The
online system implements completeness and plausibility
checks, as well as bifurcations if questions pertain only to
a subgroup of respondents. It further allows users to pause
the entry process and to store intermediary results. Upon
completion and submission of the questionnaire, the an-
swers are stored in the study database and can no longer
be changed or updated by the participant. A help desk,
located at the SMSR data center, is available via phone
and email in case of questions.
For all layer 4 data collections, participants must have
either agreed to release their medical records or to
exchange data with the SMSC in case of dual enrolment.
The SMSR data center manages all data collections and
exchanges. Medical record abstraction is performed on
site at clinics and private practices on an annual basis.
Technical aspects
The SMSR has established an online platform for survey
delivery and data collection, which also includes a pa-
tient diary, as well as features for participants to
analyze their own data. The data collection platform
was developed in close collaboration with the S3IT
(Science and IT) Division of the University of Zurich.
The backend and the frontend applications are hosted
on secure servers at the University. The backend con-
sists of a Mongo Database and a set of Python scripts
providing API functions for the frontend. The fron-
tend is programmed in Java Script Angular by a dedi-
cated Web Developer and also includes a Content
Management System for simple creation and update
of online study forms.
Security and data safety are of great concern. Safety
measures include e-mail confirmation during account
creation (double opt-in), password strength enforce-
ment, 256-TLS secured SSL communication between cli-
ents and servers, as well as strict separation of
identifiable and research data. For user administration
and access authentication, a single sign-on system was de-
veloped (Mysql, PHP), which is hosted outside the Univer-
sity of Zurich by a certified Swiss Internet provider. All
identifiable data are encrypted and IT security was
assessed by an external, specialized company.
Measurements
One particular challenge for studying MS is its multifa-
ceted manifestation. Therefore, in line with its patient-
centered design, the SMSR data collection goes well be-
yond medical information also including data on socio-
demographic factors, family history, (lifestyle) behaviors
and exposures, risk factors, patient-reported outcomes
and living and working conditions (Fig. 2). In addition,
data on the general cultural, environmental and socio-
economic conditions can be added based on where par-
ticipants live. The breadth of data collection enables
comprehensive study questions on disease burden,
causes of disease, prognostic questions, therapeutic
questions as well as research on health services for
PwMS. The following paragraphs and Table 1 provide
further details on the specific topics, as well as their
assessment frequency.
Symptoms, relapses and progression
Data on symptoms and MS progression are collected by
self-reporting in regular surveys. At baseline, participants
are instructed to indicate all symptoms they have ever ex-
perienced, the first MS symptoms they ever noticed, as
Fig. 2 Holistic ascertainment of determinants of health outcomes in
individuals affected by MS
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well as symptoms that have occurred during the past
6 months. The questionnaire further includes items on
the number of relapses and corticosteroid treatments (in-
cluding treatment settings or, where applicable, reasons
for absence of treatment initiation). This information is
updated on an annual basis in layer 3 and validated with
clinical layer 4 data where available. Aspects of mobility
are queried in layer 3 by use of the validated MS Ques-
tionnaire for Physiotherapists (MSQPT) [11].
Treatments, medication and adherence to disease-
modifying treatment (DMT)
In the layer 2 survey, participants are asked to list all
DMTs they have taken in the past 6 months, as well as
all DMTs that were ever taken. The survey also collects
basic data on alternative medications and non-pharma-
cological drug treatments. These data are updated semi-
annually in regular layer 3 questionnaires. Adherence to
DMT is assessed at least annually in layer 3 on the basis
of a short questionnaire that queries the number of
missed doses over the past 4 weeks.
Health-related quality of life
The EuroQol- 5 Dimension (EQ5D) instrument is
assessed on an annual basis [12, 13], for the first time
in layer 2. The EQ5D is also integrated in the patient
diary, which is accessible through the online data col-
lection platform. The regular follow-up questionnaires
also contain the Warwick-Edinburgh Scale [14] and the
World Health Organization (WHO) 5-item well-being
scale, which are also implemented annually [15]. In
addition, a validated single-item questionnaire on (posi-
tive) health behavior is included [16].
Mental health, depression, and fatigue
In order to assess fatigue, which represents one of the
most prominent symptoms of MS, the Modified Fatigue
Impact Scale (MFIS-21) is applied [17, 18]. In addition,
the well-established Multiple Sclerosis Impact Scale
(MSIS-29) is assessed to address physical and psycho-
logical impact from the patient perspective in the last
2 weeks. [19]
Additional questions covering aspects of mental health
and depression are assessed in specialized follow-up sur-
veys by applying the standardized Beck Depression In-
ventory (BDI)-Fast Screen [20], and Mini SPIKE [21, 22].
Circumstances of life
The layer 3 questionnaire further includes a series of ques-
tions on education, living situation, work, disability insur-
ance, social support (“Oslo 3 Social Support Scale” [23]) and
benefit finding (“Benefit Finding in MS Scale” (BFiMSS))
[24]. These questions were developed in close collaboration
with the Swiss MS Society, neuropsychologists, and PwMS.
The work history and insurance status are updated annually.
Statistical analyses
The SMSR Data Center, located at the Epidemiology,
Biostatistics and Prevention Institute of the University of
Zurich, is responsible for data collection and quality assur-
ance. Statistical analyses are performed continuously for
monitoring purposes, for data feedbacks to study partici-
pants, and for specific scientific projects. One of the
SMSR core aims is to establish a long-term, epidemio-
logical monitoring of MS in Switzerland. As no single
study is able to establish precise prevalence estimates for
MS in Switzerland, the SMSR approaches this goal by
combining information from different sources (e.g. the
SMSC) to estimate the total size of the Swiss MS popula-
tion. Thereby, the SMSR employs methods of sensitivity
analysis [25], data triangulation [26], and individual-based
mathematical modelling (e.g. [27]) in order to refine these
estimates and assess the validity of results.
Study status
Since its launch on June 25, 2016, the SMSR has enrolled
1605 persons with MS who have signed the informed con-
sent (status per September 27, 2017). Recruitment is on-
going, with 1–2 new enrolments daily. In total, 1343
persons have successfully completed the first layer 2 ques-
tionnaire. Moreover, 1005 persons also opted to partici-
pate in regular surveys and have successfully completed
the first layer 3 questionnaire, which is the starting point
for semi-annual follow-up surveys. Of those 1005 persons,
833 have already submitted a diagnosis confirmation.
Overall, 80% of participants complete the questionnaires
online, the remainder on paper.
Organization and funding
The SMSR was established at the initiative of the Swiss MS
Society, which is also the financial sponsor of the study.
The SMSR has a clearly defined governance structure and
guidelines in place to ensure a cooperative, transparent
operation. The main steering body of the SMSR is the
Scientific Assembly, which oversees the research strategy,
elects the SMSR president, and grants access to research
data. It consists of elected representatives of major MS
centers, the Swiss MS Society, the MS research com-
munity, neurorehabilitation clinics, and, last but not
least, PwMS. Scientific Assembly members bring in di-
verse professional expertise such as neurology, nursing,
physiotherapy, neuropsychology, IT, or neuroimmunol-
ogy. The Scientific Assembly is structured into three
thematic research committees, which oversee the oper-
ational aspects of the MS registry development and ini-
tiate research projects in their respective area of
expertise. The first Research Committee is concerned
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with all patient and population-based research activities
(including review of questionnaires and research instru-
ments). A second Research Committee deals with all
things related to IT, databases, and analysis of unstruc-
tured data. This IT Research Committee also initiates
and develops technology-driven registry extensions. The
third Research Committee oversees all clinical and labora-
tory research and has the lead in the development of the
layer 4 data collection.
Anonymized SMSR data are - in principle – avail-
able to all qualified researchers for specific projects.
Guidelines regulate procedures for data access, which
consist of the submission of a research proposal to
the Scientific Assembly. The proposal is then scored
according to feasibility, scientific soundness, and
alignment with overarching SMSR goals and exam-
ined by independent reviewers before being approved
by the members of the Scientific Assembly. PwMS
and the Swiss MS Society are also involved in this ap-
proval process.
Discussion
The SMSR is a longitudinal, patient-centered study,
designed to fill important knowledge gaps on MS
epidemiology and disease burden for patients in an en-
vironment where systematic compilation of routine data
from providers and/or insurers is not feasible. The close
collaboration with a patient-organization, PwMS, and
MS researchers has created a unique approach and phil-
osophy for data collection and research. In particular,
the SMSR stands out for its participatory approach to
registry development and research, a singular blend of
patient-reported and clinical data, as well as a transpar-
ent governance.
Other web-based, patient-centered initiatives in-
clude, for example, the UK MS Register, which is a
nationwide, web-based study for the UK [6], which
also has participatory elements [28]. The UK Register
gathers basic information on MS status and progres-
sion, socio-demographic factors, and a number of sev-
eral patient-reported instruments and has recruited
over 11,000 participants in 5 years [6, 29]. A second
notable example is the Dutch MS Study, which also
collects longitudinal data on quality of life and health
status by means of validated, patient-reported instru-
ments [30]. Although comparable in scope and meth-
odology, we believe that the SMSR offers additional
noteworthy features.
First, the SMSR pursues a participatory approach to
study planning and research. PwMS and the Swiss MS
Society are active contributors to the SMSR, which en-
hances motivation for participation and greatly improves
the clarity and structure of the surveys, as well as com-
munication of the findings.
Second, the layer model offers several participation op-
tions with different time commitments. The SMSR
strives to obtain basic epidemiological data from as
many PwMS as possible by means of a short one-off
survey. Participants may also opt to contribute to
semi-annual surveys, which are somewhat more
time-demanding. Other additional study modules such
as medical record abstraction come without any add-
itional workload for patients and care providers,
however.
Third, the SMSR offers regular data feedbacks for
private use and self-monitoring. Feedbacks are contex-
tualized in the whole population of study participants.
That is, participants receive additional information on
whether their specific survey response is rare or com-
mon among the other participants. Data feedbacks are
also a very efficient means to solicit data corrections
of key variables from participants.
Fourth, the SMSR has established a governance struc-
ture that involves PwMS via representation. The Scien-
tific Assembly determines the scientific strategy and
approves data requests for research. The inclusion of
patient representatives and the Swiss MS Society in gov-
erning bodies guarantees influence of the MS patient
community over project guidelines, research agenda and
data usage.
Finally, by combining traditional and novel, web-
based data collection methods the SMSR exploits the
potential of societal and technological trends while
mitigating legal and ethical risks. By offering different
participation modes (web, paper & pencil) and in the
three main national languages, the SMSR leverages
benefits of modern technology for those who wish to
participate online, without leaving less internet-savvy
persons behind. Furthermore, unlike commercial ini-
tiatives, the SMSR operates under clear regulations
and guidelines (Swiss Human Research Law), which
guarantee the rights of participants.
Therefore, while the SMSR may not be the first par-
ticipatory study in the field of MS research to take
advantage of technical innovations, in particular by pro-
viding a web portal for data collection and visualization,
it clearly takes patient participation to a new level,
thereby distinguishing itself from other international MS
registries.
Conclusion
The SMSR is an innovative, prospective study that
combines advantages of traditional and novel research
methods in medical research. Moreover, the SMSR is
unique by taking the participatory approach further
than any other study in the MS field and by covering a
large variety of domains that are relevant to PwMS’
experiences and life circumstances. What is more, the
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flexible IT infrastructure and clear governance rules
support extensions to the core protocol and data col-
lections, thus creating a future-oriented platform that
is well suited to respond to future technological inno-
vations and research trends, but also to challenges in
health care provision in MS.
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